What Did Not Work: The Drug or the Trial?

An editorial is presented on the treatment met expected pharmacodynamic targets, decreasing phosphorylated Bruton's tyrosine kinase levels, dampening plasmablast signals, and lowering anti–double-stranded DNA and IgG levels. Topics include the treatment did not demonstrate efficacy as defined by the primary end point of SLE Disease Activity Index and the many clinical trials in SLE have failed to differentiate investigational agents from placebo in prespecified primary and secondary end points.